Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults

详细信息    查看全文

• 作者：Josep Marí ; a Gatell Artigas^a ; José ; Ramó ; n Arribas Ló ; pez^b ; Pablo Lá ; zaro y de Mercado^c ; ^{plazaro@gmx.es" class="auth_mail" title="E-mail the corresponding author} ; Antonio Javier Blasco Bravo^c
• 关键词：Cost ; Efficacy ; Efficiency ; HIV ; AIDS ; Antiretroviral therapy
• 刊名：Enfermedades Infecciosas y Microbiología Clínica
• 出版年：2016
• 出版时间：August-September 2016
• 年：2016
• 卷：34
• 期：7
• 页码：427-430
• 全文大小：367 K

文摘

The National AIDS Plan and the Spanish AIDS study group (GESIDA) proposes “preferred regimens” (PR) of antiretroviral treatment (ART) as initial therapy in HIV-infected patients. In 2013, the recommended regimens were all triple therapy regimens. The Gardel Study assessed the efficacy of a dual therapy (DT) combination of lopinavir/ritonavir (LPV/r) plus lamivudine (3TC). Our objective is to evaluate the GESIDA PR and the DT regimen LPV/r + 3TC cost/efficacy ratios.

Methods

Decision tree models were built. Efficacy: probability of having viral load <50 copies/mL at week 48. ART regime cost: costs of ART, adverse effects, and drug resistance tests during the first 48 weeks.

Results

Cost/efficacy ratios varied between 5,817 and 13,930 euros per responder at 48 weeks, for the DT of LPV/r + 3TC and tenofovir DF/emtricitabine + raltegravir, respectively.

Conclusions

Taking into account the official Spanish prices of ART, the most efficient regimen was DT of LPV/r + 3TC, followed by the triple therapy with non-nucleoside containing regimens.